Medisse Closes Series B
Medisse has closed a Series B equity financing round for the clinical trial of its lead product FlexiSurge(R) Adhesion Barrier. New investor IIG has joined the existing investors, BioGeneration Ventures and Omnes Capital in the round. Medisse is active in resorbable implants for soft tissue applications, based on a patented flexible polymer platform.
29 January 2013•3 mins read
